Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:51:34.878Z.
Calculation as of: 2026-10-06T21:51:34.878Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Electra Therapeutics Inc.
Market Cap
$208.31M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$207.27M
EV/EBITDA Ratio
15.10x
TTM Avg
13.21x
3Y Avg
12.70x
5Y Avg
13.38x
Market Cap
$210.41M
EV/EBITDA Ratio
N/A
TTM Avg
14.91x
3Y Avg
15.90x
5Y Avg
15.90x
Market Cap
$205.80M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.24M
EV/EBITDA Ratio
14.36x
TTM Avg
22.76x
3Y Avg
55.61x
5Y Avg
55.61x
Market Cap
$214.46M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$215.07M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Electra Therapeutics Inc. (ETRA) | $208.31M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 15.10x | 13.21x | 12.70x | 13.38x |
| Compugen Ltd. (CGEN)vs › | $209.91M | N/A | 6.24x | 9.83x | 9.83x |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | N/A | 14.91x | 15.90x | 15.90x |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 14.36x | 22.76x | 55.61x | 55.61x |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $200.96M | N/A | 16.55x | 16.55x | 16.55x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
